NDA 220436 · Avyxa Holdings
Navitrux
Fosaprepitant Dimeglumine · Intravenous
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jun 24, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
7 Phase 3, 0 recruiting
FAERS reports
1,762
1,552 serious, 394 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
NAVITRUX, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use NAVITRUX has not been studied for the treatment of established nausea and vomiting. NAVITRUX is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use ( 1 ) NAVITRUX has not been studied for treatment of established nausea and vomiting.
Mechanism: Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK-1) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NAVITRUX · FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosaprepitant Dimeglumine" as an intervention, any sponsor and status, largest first.
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknown
Xijing HospitalAcademic, hospital or other
NCT05755659 · 3,000 participants (planned) · Start Jul 15, 2022 · Primary completion Oct 20, 2024
Drug: Fosaprepitant Dimeglumine for Injection · For: Neoplasms
Sites: Xi'an, China
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00619359 · 2,322 participants · Start Feb 2008 · Primary completion Jun 2009
Drug: Comparator: fosaprepitant dimeglumine; Comparator: Aprepitant and 3 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00337727 · 848 participants · Start Jan 1, 2007 · Primary completion Oct 28, 2008
Drug: aprepitant; Comparator: ondansetron and 4 more · For: Chemotherapy-Induced Nausea and Vomiting
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid TumorsPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT05509634 · 754 participants · Start Sep 21, 2022 · Primary completion Jun 19, 2023
Drug: HR20013 for injection;dexamethasone; fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone · For: Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Sites: Guangzhou, China
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT03578081 · 690 participants · Start Nov 20, 2018 · Primary completion Nov 8, 2021
Drug: Palonosetron Hydrochloride; Ondansetron Hydrochloride and 3 more · For: Malignant Neoplasm
Sites: Birmingham, Alabama; Fairbanks, Alaska; Kingman, Arizona · 566 sites in all
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.Pivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT07081256 · 665 participants · Start Jan 3, 2025 · Primary completion Aug 25, 2025
Drug: QLM2010 for injection;dexamethasone; fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Hangzhou, China
- Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly CisplatinPivotal-lookingCompleted
Odense University HospitalAcademic, hospital or other
NCT01074697 · 246 participants · Start Apr 2010 · Primary completion Apr 2015
Drug: Fosaprepitant dimeglumine; Placebo · For: Nausea; Vomiting; Genital Neoplasms, Female
Sites: Adelaide SA, Australia; Aarhus, Denmark; Copenhagen, Denmark · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea329
- infusion related reaction291
- alopecia256
- fatigue248
- hypersensitivity241
- pyrexia231
- arthralgia229
- confusional state223
- glossodynia220
- helicobacter infection219
- duodenal ulcer perforation217
- discomfort214
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 29 |
| 2014 | 53 |
| 2015 | 48 |
| 2016 | 58 |
| 2017 | 63 |
| 2018 | 97 |
| 2019 | 92 |
| 2020 | 118 |
| 2021 | 140 |
| 2022 | 200 |
| 2023 | 166 |
| 2024 | 215 |
| 2025 | 282 |
| 2026 | 186 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study.
Lu K, Lin S, Wang Y, et al. · Clin Pharmacol Drug Dev 2021 · Comparative Study, Randomized Controlled Trial
- A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A, Gangadharan VP, Desai CJ, et al. · Indian J Cancer 2013 · Clinical Trial, Phase III, Randomized Controlled Trial
- Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C, Jordan K, Green SA, et al. · Ann Oncol 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C, Jordan K, Green SA, et al. · Support Care Cancer 2018 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.